0001477932-22-002177.txt : 20220408
0001477932-22-002177.hdr.sgml : 20220408
20220408160217
ACCESSION NUMBER: 0001477932-22-002177
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220407
FILED AS OF DATE: 20220408
DATE AS OF CHANGE: 20220408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: TERRELL JASON BRADLEY MD
CENTRAL INDEX KEY: 0001567531
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36833
FILM NUMBER: 22816943
MAIL ADDRESS:
STREET 1: 13215 BEE CAVE PARKWAY,
STREET 2: SUITE 125, GALLERIA OAKS B
CITY: AUSTIN
STATE: TX
ZIP: 78738
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VOLITIONRX LTD
CENTRAL INDEX KEY: 0000093314
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 911949078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 13215 BEE CAVE PARKWAY,
STREET 2: SUITE 125, GALLERIA OAKS B
CITY: AUSTIN
STATE: TX
ZIP: 78738
BUSINESS PHONE: 1 (646) 650-1351
MAIL ADDRESS:
STREET 1: 13215 BEE CAVE PARKWAY,
STREET 2: SUITE 125, GALLERIA OAKS B
CITY: AUSTIN
STATE: TX
ZIP: 78738
FORMER COMPANY:
FORMER CONFORMED NAME: STANDARD CAPITAL CORP
DATE OF NAME CHANGE: 19990812
4
1
form4.xml
FORM 4
X0306
4
2022-04-07-05:00
false
0000093314
VOLITIONRX LTD
VNRX
0001567531
TERRELL JASON BRADLEY MD
13215 BEE CAVE PARKWAY,
SUITE 125, GALLERIA OAKS B
AUSTIN
TX
78738
false
true
false
false
Chief Medical Officer
Common Stock
2022-04-07-05:00
4
A
false
12300
0
A
37249
D
Common Stock
2022-04-07-05:00
4
A
false
955
0
A
955
I
By Spouse
Stock Option (Right to Buy)
3.40
2022-04-07-05:00
4
A
false
22668
0
A
2031-08-03-05:00
Common Stock
22668
22668
D
Stock Option (Right to Buy)
3.40
2022-04-07-05:00
4
A
false
1760
0
A
2031-08-03-05:00
Common Stock
1760
1760
I
By Spouse
On August 3, 2021, the reporting person was awarded 35,145 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,300 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 6,150 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
On August 3, 2021, the spouse of the reporting person was awarded 2,730 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 955 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 477 units and 478 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the spouse of the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
On August 3, 2021, the reporting person was granted an option to purchase 64,766 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 22,668 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 11,334 shares on each of August 3, 2022 and August 3, 2023, respectively.
On August 3, 2021, the spouse of the reporting person was granted an option to purchase 5,030 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,760 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 880 shares on each of August 3, 2022 and August 3, 2023, respectively.
/s/ Jason Bradley Terrell MD
2022-04-08-05:00